New Elite Feature: Chart Templates — Your indicators and design everywhere on Finviz

Structure Therapeutics Inc.

Contributing Author

Recent Articles by Structure Therapeutics Inc.

Mar-16	Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron GPCR +5.40% GlobeNewswire
Feb-26	Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights GPCR GlobeNewswire
Dec-17	Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity GPCR GlobeNewswire
Dec-11	Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs GPCR GlobeNewswire
Dec-09	Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants GPCR GlobeNewswire
Dec-08	Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants GPCR +102.49% GlobeNewswire
Dec-08	Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron GPCR +102.49% GlobeNewswire
Dec-07	Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025 GPCR GlobeNewswire
Nov-06	Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights GPCR GlobeNewswire
Sep-02	Structure Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences GPCR GlobeNewswire
Aug-06	Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights GPCR GlobeNewswire
Jun-20	Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671 GPCR GlobeNewswire
May-29	Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences GPCR GlobeNewswire
May-08	Structure Therapeutics Reports First Quarter 2025 Financial Results and Recent Highlights GPCR GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)